Transaction details
Mirum Pharmaceuticals (NASDAQ: MIRM) Chief Financial Officer Eric Bjerkholt reported selling 7,287 shares of the company's common stock on March 16, 2026. The shares traded at $91.9779 per share, producing gross proceeds of about $670,242. According to a Form 4 filing with the Securities and Exchange Commission, the sale was executed to cover tax withholding obligations associated with the vesting of performance restricted stock units.
The filing also notes that on March 15, 2026, Bjerkholt exercised options on 13,334 shares of Mirum Pharmaceuticals common stock.
Market performance and valuation
Mirum's share price has advanced to $96.60, marking a 114% gain over the prior 12 months. Despite the stock's strong run, InvestingPro analysis indicates the shares are currently overvalued relative to its Fair Value and places Mirum among the most overvalued stocks in the market. Investors have access to 13 additional InvestingPro Tips for further perspective on MIRM's valuation and prospects.
The platform also references a Fair Value calculator that uses a mix of 17 proven industry valuation models to estimate intrinsic value for MIRM and other stocks.
Operational results and clinical progress
In its fiscal 2025 results, Mirum disclosed Livmarli sales of $360 million, with approximately $245 million of that amount generated in the United States. The company reported this represented 69% year-over-year sales growth, which the company attributed to new patient additions in Alagille Syndrome and increased uptake in adult Progressive Familial Intrahepatic Cholestasis (PFIC).
Mirum has completed enrollment in the Phase 3 EXPAND study for Livmarli, a trial aimed at treating cholestatic pruritus in patients with rare cholestatic liver diseases.
The company has also reached enrollment milestones in its hepatitis delta virus program, completing enrollment in the Phase 3 AZURE 1 study and conducting screening in the Phase 3 AZURE 4 study.
Analyst coverage
Brokerage actions have varied recently. Leerink Partners adjusted its price target for Mirum to $118 from $120 while maintaining an Outperform rating. Evercore ISI raised its price target to $126, citing Mirum's expanding business and pipeline developments. Citizens and Morgan Stanley reiterated favorable views, maintaining Market Outperform and Overweight ratings, respectively.
Taken together, the insider transaction, the company's reported revenue growth, clinical trial progress, and analyst commentary provide a multifaceted snapshot of Mirum at this point in its commercial and clinical trajectory.